Biotechnology US biotech firm BioMarin Pharmaceutical saw its shares close down 9.6% at $81.24 on Monday, after it announced positive top-line results from its ongoing global Phase III GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, which has been issued two brand names – Roctavian and Valrox. 12 January 2021